Our team

Our Lab

Ability Pharmaceuticals, SL has built and excellent research group composed by one postdoctoral research fellow, one Ph.D. student and one research technician, that perform all experimental procedures in cellular biology, molecular biology, proteomics and animal models for human cancers. The Lab is coordinated by Dr. Hector Perez-Montoyo, who is the Director of Biological Research of AbilityPharma. The Lab uses facilities of the Autonomous University of Barcelona (cell cultures, animal laboratory, cellular and genetic biology and biochemistry), in a collaboration established with Dr. José Miguel Lizcano, from the Department of Biochemistry and Molecular Biology at UAB.

The formation of the AbilityPharma Lab has allowed us to fully characterize the mechanism of action of ABTL0812, and to investigate new therapeutic scenarios for ABTL0812 and follow-ups. It has also facilitate the development of novel biomarkers and perform all pre-clinical studies needed to advance in the research pipeline of our compounds. On the clinical site, the Lab analyses the human patient samples from the clinical trial currently ongoing for the identification and validation of novel biomarkers to monitor and to predict efficacy, therefore allowing us to select the group of patients that will better respond to the treatment in future clinical studies, improving their success outcome.
 
Our Lab actively collaborates with other public institutions and research groups from different universities, research centers and hospitals (Vall d´Hebron-VHIO, Clinic Hospital-IDIBAPS, IRBLleida, UdG, Bellvitge Universitary Hospital), having built a network of expert scientists who by sharing their knowledge, expertise and results, have allowed AbilityPharma to optimize the efforts and resources to direct research to a common goal: “improve people´s life by providing novel cancer drugs”.

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG